PLCB1 and hydrops fetalis: Based on our in vitro and in vivo data, we believe CTP‐miRNA106a could address an unmet medical need for delivery of a molecular therapeutic to treat HF that goes directly to cardiomyocytes and acts on HF hub signalling pathways such as CAMKIIδ, PLCβ1, and NF‐κB pathways.